Treatment-induced changes in 31P-MRS (magnetic resonance spectroscopy) spectra of sera from patients with acute leukemia.
31P-nuclear magnetic resonance (NMR) spectra were obtained in vitro from sera of 40 healthy volunteers and 30 patients with acute leukemia (AL) at the time of diagnosis and repeated up to 2-13 times during therapy. All spectra consisted of inorganic phosphate (Pi) peak (used as a reference peak) and two peaks from phospholipids (PL): one peak due to phosphatidylethanolamine and sphingomyelin (PE + SM) and second peak due to phosphatidylcholine (PC). Prior to initiation of therapy 31P spectra of sera of patients with acute leukemia differed from spectra of sera of normal individuals. Peak intensities of the PL were low in relation to Pi. During therapy leading to remission, resonance from PL progressively increased approximately to the spectral pattern in normal sera. Contrary to that, in non-responders the intensities of the phospholipids peaks remained unchanged. Long-term follow-up 31P-MRS studies showed not only a good correlation between this 31P-MRS evolution of sera and the response to the therapy but also showed changes in phospholipids' levels in the following days during and after therapy. Moreover, correlations were found between high-density lipoprotein (HDL), cholesterol (CHOL) and low-density lipoprotein (LDL) concentrations measured by conventional techniques and peak intensities of PC and of PE + SM acquired by 31P-MRS.
Kuliszkiewicz-Janus
M
M
Department of Haematology, Wrocław University of Medicine, Poland.
Baczyński
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D001752:Blast Crisis / Q000097:blood; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000097:blood* / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000097:blood* / Q000628:therapy; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood*; D010743:Phospholipids / Q000097:blood*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood* / Q000628:therapy; D012074:Remission Induction
D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D010710:Phosphates; D010743:Phospholipids; D002784:Cholesterol